Expression of PCAF, p300 and Gcn5 and more highly acetylated histone H4 in pediatric tumors

Journal of Experimental and Clinical Cancer Research

Volumn 26, Issue 2, 2007, Pages 269-276

  Armas Pineda, C ^a   Arenas Huertero, Francisco ^a,c   Perezpena Diazconti M ^a   Chico Ponce De Leon, F ^a   Sosa Sainz G ^a   Lezama, P ^a   Recillas Targa, F ^b  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Acetylation; Astrocytoma; Chromatin; HATs; Histone H4; Tumors

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE GCN5; HISTONE ACETYLTRANSFERASE PCAF; HISTONE H4; PROTEIN P300;

ACETYLATION; ARTICLE; BENIGN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHROMATIN STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NEPHROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACETYLATION; CELL CYCLE PROTEINS; CHILD; GENE EXPRESSION; HISTONE ACETYLTRANSFERASES; HISTONES; HUMANS; NEOPLASMS; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 34347381275     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Moggs J. G., Goodman J. I., Trosko J. E., Roberts R. A.: Epigenetics and cancer: implications for drug discovery and safety assessment. Toxicol. Appl. Pharmacol. 196: 422-4301, 2004.
2. Hake S. B., Xiao A., Allis C. D.: Linking the epigenetic "language" of covalent histone modifications to cancer. Br. J. Cancer. 90: 761-769, 2004.
3. Sterner D. E., Berger S. L.: Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 64: 435-459, 2000.
4. Arenas-Huertero F., Recillas-Targa R: Modificaciones epigenéticas de la cromatina en la generación de cáncer. Gac. Méd. México. 138: 547-555, 2002.
5. Davie J. R., Spencer V. A.: Control of histone modifications. J. Cell. Biochem. Suppl. 32/33: 141-148, 1999.
6. Wang S., Yan-Neale Y., Zeremski M., Cohen D.: Transcription regulation by histone deacetylases. Novartis Found. Symp. 259: 238-245, 2004.
7. Chan H. M., La Thange N. B.: p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J. Cell. Sci. 114: 2363-2373, 2001.
8. Roth S. Y., Denu J. M., Allis C. D.: Histone acetyltransferases. Annu. Rev. Biochem. 70: 81-120, 2001.
9. Schiltz R. L., Nakatani Y.: The PCAF acetylase complex as a potential tumor suppressor. Biochem. Biophys. Acta. 1470: M37-M53, 2000.
10. Liu X., Tesfai J., Eurard I. A., Dent S. Y. R., Martinez E.: c-Myc transformation domain recruits the human STAGA complex and requires TRRAP and Gcn5 acetylase activity for transcription. J. Biol. Chem. 278: 20405-20412, 2003.
11. Suganuma T., Kawabata M., Oshima T., Ikeda M-A.: Growth suppression of human carcinoma cells by reintroduction of the p300 coactivator. Proc. Natl. Acad. Sci. U.S.A. 99: 13073-13078, 2002.
12. Yoshida M., Kijima M., Akita M., Beppu T.: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265: 17174-17179, 1990.
13. Davis P. K., Brackmann R. K.: Chromatin remodeling and cancer. Cancer Biol. Ther. 2: 22-29, 2003.
14. Brown K. E.: Chromatin folding and gene expression: new tools to reveal the spatial organization of genes. Chromosome Res. 11: 423-433, 2003.
15. Fraga M. F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., Gopalakrishna I., Pérez-Rosado A., Calvo E., Lopez J. A., Cano A., Calasanz M. J., Colomer D., Piris M. A., Ahn N., Imhof A., Caldas C., Jenuwein T., Esteller M.: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genetics. 37: 391-400,2005.
16. Zhu Y., Parada L. E: The molecular and genetic basis of neurological tumors. Nature Rev. Cancer. 2: 616-626, 2002.
17. Ozdag H., Teschendorff A. E., Ahmed A. A., Hyland S. J., Blenkiron C., Bobrow L., Veerakumarasivam A., Burtt G., Subkhankulova T., Arends M. J., Collins V. P., Bowtel D., Kouzarides T., Brenton J. D., Caldas C.: Differential expression of selected histone modifier genes in human solid cancers. B.M.C. Genomics. 7: 1-46, 2006.
18. Lang S. E., McMahon S. B., Cole M. D., Hearing P.: E2F transcriptional activation requires TRRAP and Gcn5 cofactors. J. Biol. Chem. 276: 32627-32634, 2001.
19. Toh Y., Yamamoto M., Endo K., Ikeda Y., Baba H., Kohnoe S., Yonemasu H., Hachitanda Y., Okamura T., Sugimachi K.: Histone H4 acetylation and histone deacetylase I expression in esophageal squamous cell carcinoma. Oncol. Rep. 10: 333-338, 2003.
20. Seligson D. B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S. K.: Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 435: 1262-1266, 2005.
21. Ono S., Oue N., Kuniyasu H., Suzuki T., Ito R., Matsusaki K., Ishikawa T., Tahara E., Yasui W.: Acetylated histone H4 is reduced in human gastric adenomas and carcinomas. J. Exp. Clin. Cancer Res. 21: 377-382, 2002.
22. Anton M., Horky M., Kuchtickova S., Vojtesek B., Blaha O.: Immunohistochemical detection of acetylation and phosphorylation of histone H3 in cervical smears. Ceska. Gynekol. 69: 3-6, 2004.